IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.704
AS - Asia 1.549
EU - Europa 794
SA - Sud America 377
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 6.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.631
SG - Singapore 857
CN - Cina 398
BR - Brasile 325
FI - Finlandia 177
IT - Italia 140
IE - Irlanda 110
DE - Germania 84
NG - Nigeria 64
HK - Hong Kong 57
CA - Canada 53
VN - Vietnam 52
NL - Olanda 51
GB - Regno Unito 48
IN - India 47
FR - Francia 40
SE - Svezia 40
BD - Bangladesh 25
JP - Giappone 21
BE - Belgio 20
AR - Argentina 19
TR - Turchia 16
EC - Ecuador 12
MX - Messico 12
RU - Federazione Russa 12
CL - Cile 11
CZ - Repubblica Ceca 11
PL - Polonia 11
UZ - Uzbekistan 10
ES - Italia 9
IL - Israele 9
AT - Austria 8
ZA - Sudafrica 8
EG - Egitto 7
IQ - Iraq 7
ID - Indonesia 6
IR - Iran 6
PK - Pakistan 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
EU - Europa 5
PT - Portogallo 5
SA - Arabia Saudita 5
AU - Australia 4
KE - Kenya 4
KR - Corea 4
PE - Perù 4
AZ - Azerbaigian 3
KG - Kirghizistan 3
LT - Lituania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AF - Afghanistan, Repubblica islamica di 2
BG - Bulgaria 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
MA - Marocco 2
NO - Norvegia 2
NP - Nepal 2
PY - Paraguay 2
RO - Romania 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
IM - Isola di Man 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TV - Tuvalu 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.527
Salva come PNG Salva come JPEG
Città #
Dallas 648
Chandler 516
Wilmington 409
Singapore 255
The Dalles 189
Shanghai 181
Ashburn 176
Helsinki 176
San Mateo 162
Ann Arbor 131
Beijing 121
Dublin 109
Boardman 97
New York 92
Lawrence 82
Princeton 82
Leawood 77
Benin City 64
Milan 51
Amsterdam 46
Hong Kong 42
Paris 38
Phoenix 37
Woodbridge 30
Los Angeles 27
Seattle 27
São Paulo 24
London 23
Santa Clara 23
Fairfield 22
Ho Chi Minh City 22
Toronto 19
Brussels 18
Pune 18
San Diego 15
Munich 14
Montreal 13
Rio de Janeiro 11
Warsaw 11
Brooklyn 9
Kocaeli 9
Naples 9
Porto Alegre 9
Tashkent 9
Abbiategrasso 8
Hanoi 8
Andover 7
Atlanta 7
Council Bluffs 7
Norwalk 7
Salvador 7
San Francisco 7
Belo Horizonte 6
Brno 6
Chennai 6
Monmouth Junction 6
Redwood City 6
Brasília 5
Cairo 5
Chicago 5
Columbus 5
Dhaka 5
Guayaquil 5
Jeddah 5
Johannesburg 5
Raleigh 5
Redmond 5
Ribeirão Preto 5
Tokyo 5
Umeda 5
Assago 4
Baghdad 4
Curitiba 4
Falls Church 4
Mexico City 4
Porto 4
Reston 4
Shenzhen 4
Tai Kok Tsui 4
Winnipeg 4
Aparecida de Goiânia 3
Bishkek 3
Boston 3
Canoas 3
Da Nang 3
Denver 3
Falkenstein 3
Florence 3
Franca 3
Guangzhou 3
Hanover 3
Houston 3
Istanbul 3
Jakarta 3
Manchester 3
Moscow 3
Nairobi 3
Niterói 3
Pelotas 3
Petrópolis 3
Totale 4.396
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 129
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 108
Tivantinib for hepatocellular carcinoma 100
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 98
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 97
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 95
COVID-19 and liver cancer clinical trials: not everything is lost 92
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 92
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 89
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 87
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 87
Biomarkers in Hepatocellular Carcinoma-Letter 85
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 84
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 82
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 82
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 81
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 81
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 80
Cabozantinib for the treatment of hepatocellular carcinoma 79
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 79
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 79
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 79
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 76
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 74
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 73
Reply to Y. Pointreau et al 73
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 71
Role of liver biopsy in hepatocellular carcinoma 71
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 70
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 69
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 69
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 68
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 68
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 68
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 68
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 68
Shaping the landscape of immune oncology in hepatocellular carcinoma 67
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 67
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 67
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 66
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 66
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 66
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 66
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 66
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 65
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 65
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 64
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 64
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 64
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 64
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 63
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 63
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 63
Regorafenib for the treatment of unresectable hepatocellular carcinoma 62
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 61
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 60
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 60
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 60
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 59
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 59
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 59
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 57
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 57
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 56
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 56
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 55
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 55
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 55
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 55
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 54
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 53
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 53
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 52
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 51
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 50
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 50
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 49
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 48
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 48
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 47
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 47
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 46
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 46
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 44
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 43
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 42
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 41
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 40
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 40
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 40
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 39
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 39
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 39
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 39
OncoAlert round table discussions: The global COVID-19 experience 38
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 37
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 37
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 36
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 34
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 33
Totale 6.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.817
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.817
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021719 0 0 0 0 0 230 118 46 134 95 10 86
2021/2022553 15 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/20261.752 492 668 176 314 80 22 0 0 0 0 0 0
Totale 6.684